Highly efficient light-driven hydrogen evolution utilizing porphyrin-based nanoparticles.

We developed dye-sensitized photocatalytic systems (DSPs) by utilizing porphyrins as a photosensitizer (PS) or as a photosensitizer-catalyst (PS/CAT) upon their chemisorption onto platinum-doped titanium dioxide nanoparticles (Pt-TiO2 NPs). The DSPs coated with Pt-Tc3CP (PS/CAT entity) exhibited a record-high stability (25 500 TONs) and H2 evolution activity (707 mmol g-1 h-1) compared to similar DSPs in the literature.

A comparative study of outcomes of burns across multiple levels of care.

BACKGROUND: Burn injuries are a significant contributor to the burden of diseases. The management of burns at specialised burn centres has been shown to improve survival. However, in low- and middle-income countries (LMICs) major burns are managed at non-specialised burn centres due to resource constraints. There is insufficient data on survival from treatment at non-specialised burn centres in LMICs. This study aimed to compare the outcomes of burns treatment between a specialised burn centre and five non-specialised centres. METHODS: A prospective cohort study was conducted on patients aged 18 years or above from January 1, 2021 to September 30, 2021. Participants were selected from the admission register at the emergency department. All burns irrespective of the mechanism of injury or %TBSA were included. Data were entered into REDCap. Statistical analysis of outcomes such as positive blood culture, length of hospital stay (LOHS) and 90-day mortality between specialised burn versus non-specialised centres was performed. Furthermore, an analysis of risk factors for mortality was performed and survival data computed. RESULTS: Of the 488 study participants, 36% were admitted to a specialised burn centre compared to 64% admitted to non-specialised centres. The demographic characteristics were similar between centres. Patients at the specialised burn centre compared to non-specialised centres had a significantly higher inhalation injury of 30.9% vs 7.7% (p < 0.001), > 10%TBSA at 83.4% vs 45.7% (p < 0.001), > 20%TBSA at 46.9% vs 16.6% (p < 0.001), and a median (IQR) ABSI score of 6 (5-7) vs 5 (4-6) (p < 0.0001). Furthermore, patients from specialised burn vs non-specialised centres had a longer median (IQR) time from injury to first burn excision at 7 (4-11) vs 5 (2-10) days, higher rate of burn sepsis 69% vs 35%, increased LOHS 17 (11-27) vs 12 (6-22) days, and 90-day mortality rates at 19.4% vs 6.4%. After adjusting for cofounding variables, survival data showed no difference between specialised burn and non-specialised centres (HR 1.8 95% CI 1.0-3.2, p = 0.05). CONCLUSION: Although it appears that the survival of burn patients managed at non-specialised centres in a middle-income country is comparable to those managed at specialised burn centres, there is uncounted bias in our survival data. Hence, a change in practice is not advocated. However, due to resource constraint specialised burn centres in addition to managing major burns should provide training and support to the non-specialised centres.

Collecting and Culturing Bryozoans for Regenerative Studies.

Among marine invertebrates, bryozoans are small, not well known, and complex to identify. Nevertheless, they offer unique opportunities for whole-body generation research, because of their colonial, modular mode of growth. Here, we describe detailed methods for collection of bryozoans from a range of environments, sample preparation and identification, culture and feeding, spawning and breeding, marking colonies for growth studies, and histological preparation.

A case of mistaken identity: An unusual presentation of neoplastic meningitis and a reminder of the hallmark features.

This case offers an opportunity for education on the manifestations of neoplastic meningitis, a revision of the hallmark investigative features, and a reminder of the utilization of lumbar puncture in investigating unexplained neurological symptoms. Additionally, it emphasises the need for clinicians to avoid "diagnostic anchoring" when faced with recurrent attenders.

Cellaria (Bryozoa, Cheilostomata) from the deep: new species from the southern Zealandian region.

Collections from relatively deep waters around the New Zealand Exclusive Economic Zone have revealed new species in the cheilostome bryozoan genus Cellaria sensu lato. We describe here seven new species: C. calculosa n. sp., C. curiosa n. sp., C. gracillima n. sp., C. major n. sp., C. spatulifera n. sp., C. stenorhyncha n. sp. and C. macricula n. sp. previously misidentified as C. humilis Moyano, 1983. Four additional species (here called spp. 1, 2, 3, 4) are left in open nomenclature since not enough key taxonomic characteristics were observed to define them as new. Furthermore, some of the newly described species have combinations of taxonomic characters that overlap with those said to characterise Paracellaria and Euginoma. The New Zealand region holds the highest species diversity of Cellaria sensu lato in the world.

A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis.

OBJECTIVE: A feasibility study to assess efficacy and safety of modified release (MR) prednisone (Lodotra™) compared to immediate release (IR) prednisolone in patients with newly diagnosed giant cell arteritis (GCA). METHODS: Twelve patients with new diagnosis of GCA were initially treated with high-dose prednisolone (40-60 mg) daily for 4 weeks and then randomized to two open arms to continue tapering steroid treatment with either standard IR prednisolone or MR prednisone. Patients were reviewed every 2 weeks either face to face or by telephone, for a total of 26 weeks. Disease activity, steroid-related side effects, sleep disturbance, fatigue scores and blood tests were systematically monitored. The primary endpoint (efficacy) was defined as the proportion of patients achieving persistent clinical disease control (without features of active disease and remaining flare free at 26 weeks) in each arm. RESULTS: At 26 weeks, 6/7 patients taking MR prednisone were in persistent control, compared with 4/5 receiving IR prednisone. One patient in each group suffered a disease flare necessitating an increased steroid dose. There were no statistically significant differences between the groups in terms of reduction in inflammatory markers, Health Assessment Questionnaire, visual analogue scale, fatigue and improvement in EuroQol 5D scores. CONCLUSION: This trial shows that MR prednisone appears to be a safe and effective treatment for GCA with a similar outcome profile to standard IR prednisolone.

Solitary atrial metastases: a rare clinical challenge.

This case describes a 55-year-old lady presenting with lethargy, migraines and a cardiac mass on a background history of breast cancer. She had been treated initially with a mastectomy, axillary node clearance, reconstruction and hormone manipulation followed by chemotherapy and high dose radiotherapy for an isolated supraclavicular metastases. She was disease free for 5 years when she complained of lethargy and migraines. A CT confirmed an isolated cardiac lesion, confirmed on echocardiogram A percutaneous atrial biopsy revealed an atrial metastases from breast carcinoma. She was treated with chemotherapy achieving a good response but was still deemed inoperable after treatment. She currently is receiving letrozole.